Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021)

pulmonary hypertension, pulmonary arterial hypertension, congenital heart disease, pulmonary vascular disease, surgery, atrioseptostomy, specific therapy, guidelines

1. Chazova I.E., Martynyuk T.V., Valieva Z.S., et al). EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122

2. Baumgartner H., De Backer J., Babu-Naraya S.V., et al. 2020 ESC Guidelines for the management of adult congenital heart disease: The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD). Eur Heart J. 2021; Vol. 42 (6): 563–645. https://doi.org/10.1093/eurheartj/ehaa554

3. Frost A., Badesch D., Simon J.R., et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019; 53: 1801904. https://doi.org/10.1183/13993003.01904-2018

4. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016; 37: 67–119. https://doi.org/10.1183/13993003.01032-2015

5. Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow: LLC «Medical Information Agency», 2018: 304 р. (In Russ.)

6. Chazova I.E., Arkhipova O.A., Martynyuk T.V. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry // Terapevticheskii arkhiv. 2019; Vol. 91 (1):25-31. (In Russ.) https://doi.org/10.26442/00403660.2019.01.000024

7. Dimopoulos K., Wort S.J., Gatzoulis M.A. Pulmonary hypertension related to congenital heart disease: A call for action. Eur Heart J. 2014; 35:691–700. https://doi.org/10.1093/eurheartj/eht437

8. Lowe B.S., Therrien J., Ionescu-Ittu R., et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population: impact on outcomes. J Am Coll Cardiol. 2011; 58: 538–46. https://doi.org/10.1016/j.jacc.2011.03.033

9. Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian clinical guidelines, 2020 (In Russ.) http://cr.rosminzdrav.ru/#!/recomend/137

10. Kovacs G., Berghold A., Scheidl S., et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34 (4): 888–94. https://doi.org/10.1183/09031936.00145608

11. Kaemmerer H., Apitz C., Brockmeier K., et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J of Cardiology. 2018; 272: 79–88. https://doi.org/10.1016/j.ijcard.2018.08.078

12. Gorbachevsky S.V., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Definition, classification and initial examination of patients. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(5):28-37. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-5-28-37

13. Rosenzweig E.B., Abman S.H., Adatia I., et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019; 53(1). https://doi.org/10.1183/13993003.01916-2018

14. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62 (25 Suppl): D34-41. https://doi.org/10.1016/j.jacc.2013.10.029

15. Cantor W.J., Harrison D.A., Moussadji J.S., et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome, Am J. Cardiol. 1999; 84: 677–81. https://doi.org/10.1016/S0002-9149(99)00415-4

16. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-537. https://doi.org/10.1093/eurheartj/ehp297

17. Stout K.K., Daniels C.J., Aboulhosn J.A., et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e698-e800. https://doi.org/10.1161/CIR.0000000000000603

18. Bockeria L.A., Gorbacheusky S.V., Shmalts A.A., et al. Hemodinamic correction of the single functional ventricle after prior pulmonary arterial narrowing. Russian Journal of Thoracic and Cardiovascular Surgery. 2008; 5:27-34 (In Russ.)

19. Bockeria L.A., Gorbachevskiy S.V., Shmal’s A.A. Pulmonary arterial hypertension associated with congenital heart disease in adults (clinical guidelines). Grudnaya i Serdechno-Sosudistaya Khirurgiya, Thoracic and Cardiovascular Diseases, Russian journal). Grudnaya i serdechno-sosudistaya khirurgiya (Russian Journal of Thoracic and Cardiovascular Surgery).2017; 59(2):135–147. (In Russ). https://doi.org/10.24022/0236-2791-2017-59-2-135-147

20. Pulmonary hypertension in children. Russian clinical guidelines, 2017 (In Russ). http://cr.rosminzdrav.ru/#!/recomend/901

21. Hypertensive pulmonary vascular disease associated with congenital heart disease in children. Russian clinical guidelines, 2018 (In Russ). http://cr.rosminzdrav.ru/#!/schema/356

22. Cerro M.J., Abman S., Diaz G., et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; 1(2):286– 98. https://doi.org/10.4103/2045-8932.83456

23. Chazova I.E., Martynyuk T.V. Pulmonary hypertension. Moscow. Practice. 2015, 928 p. (In Russ.)

24. Apitz C., Hansmann G., Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2): ii23–9. http://dx.doi.org/10.1136/heartjnl-2014-307340

25. Moceri P., Kempny A., Liodakis E., et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol. 2015; 179:455–460. https://doi.org/10.1016/j.ijcard.2014.11.100

26. Kozlik-Feldmann G., Hansmann, D., et al. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK, Heart 2016; 102 (Suppl 2): i42-ii8. http://dx.doi.org/10.1136/heartjnl-2015-308378

27. van der Linde D., Konings E.E., Slager M.A., et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241-47. https://doi.org/10.1016/j.jacc.2011.08.025

28. Liu Y., Chen S., Zuhlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019; 48:455-46. https://doi.org/10.1093/ije/dyz009

29. Lytzen R., Vejlstrup N., Bjerre J., et al. Live-born major congenital heart disease in Denmark: incidence, detection rate, and termination of pregnancy rate from 1996 to 2013. JAMA Cardiol 2018; 3: 829-37. https://doi.org/10.1001/jamacardio.2018.2009

30. Moons P., Bovijn L., Budts W., et al. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010; 122: 2264-72. https://doi.org/10.1161/CIRCULATIONAHA.110.946343

31. MarelliA.J., Ionescu-Ittu R., MackieA.S., et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014; 130: 749-56. https://doi.org/10.1161/CIRCULATIONAHA.113.008396

32. Van de Bruaene A., Delcroix M., Pasquet A., et al. The Belgian Eisenmenger syndrome registry: Implications for treatment strategies? Acta Cardiol. 2009;64: 447–53. https://doi.org/10.2143/AC.64.4.2041608

33. van Riel A.C., Schuuring M.J., van Hessen I.D., et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014; 174: 299-305. https://doi.org/10.1016/j.ijcard.2014.04.072

34. Manes A., Palazzini M., Leci E., et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014; 35: 716-24. https://doi.org/10.1093/eurheartj/eht072

35. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004. 126 (1 Suppl):78S–92S. https://doi.org/10.1378/chest.126.1_suppl.78S

36. Marelli A.J., Mackie A.S., Ionescu-Ittu R., et al. Congenital heart disease in the general population: Changing prevalence and age distribution. Circulation. 2007; 115:163–72. https://doi.org/10.1161/CIRCULATIONAHA.106.627224

37. Duffels M.G., Engelfriet P.M., Berger R.M. et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007; 120(2):198-204. https://doi.org/10.1016/j.ijcard.2006.09.017

38. Ramjug S., Hussain N., Hurdman J. et al. Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic-pathophysiologic classification. J Heart Lung Transplant. 2016. 35(5):610-18. https://doi.org/10.1016/j.healun.2015.12.016

39. Diller G.P., Dimopoulos K., Kafka H., et al. Model of chronic adaptation: Right ventricular function in Eisenmenger syndrome. Eur. Heart J. Suppl. 2007; 9:H54–H60. https://doi.org/10.1093/eurheartj/sum019

40. Alonso-Gonzalez R., Lopez-Guarch C.J., Subirana-Domenech M.T., et al. Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. Int J Cardiol. 2015; 184:717-23. https://doi.org/10.1016/j.ijcard.2015.02.031

41. Kempny A., Hjortshøj C.S., Gu H., et al. Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study. Circulation. 2017;135(15):1432-1440. https://doi.org/10.1161/CIRCULATIONAHA.116.023033

42. Morse J.H., Barst R.J., Fotino M. Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. Am Rev Respir Dis. 1992; 145:787–92. https://doi.org/10.1164/ajrccm/145.4_Pt_1.787

43. Roberts K.E., McElroy J.J., Wong W.P., et. al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J. 2004; 24:371–74. https://doi.org/10.1183/09031936.04.00018604

44. Bockeria L.A., Gorbachevskiy S.V., Shmal’s A.A. Pulmonary arterial hypertension associated with congenital heart disease in adults. Methodological manual. Bakoulev SCCS RAMS. 2016. 28 p. ISBN 978-5-7982-0368-0 (In Russ.)

45. Khugaev GA, Shmalts AA. Morphological assessment of pulmonary vessels in pulmonary arterial hypertension associated with congenital heart disease. Arkhiv Patologii. 2021;83(5):49-57. (In Russ.) https://doi.org/10.17116/patol20218305149

46. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122 (12):4306-13. https://doi.org/10.1172/JCI60658

47. Iacobazzi D., Suleiman M.S., Ghorbel M., et al. Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart. 2016; 102(1):12-7. https://doi.org/10.1136/heartjnl-2015-308348

48. Bradford R., Tulloh R. Diagnosis and management of pulmonary hypertension in adult congenital heart disease. Br J Cardiac Nurs. 2008; 3:138–45.

49. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001. 120(5):1562-69. https://doi.org/10.1378/chest.120.5.1562

50. Gorbachevsky Sv., Shmalts A.A. What can cause pulmonary vascular disease in functionally single ventricle? Anatomy & Physiology: Current Research. 2016; 6 (1). https://doi.org/10.4172/2161-0940.1000e137

51. Adatia I., Kothari S.S., Feinstein J.A. Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. Chest 2010; 137(6):52-61. https://doi.org/10.1378/chest.09-2861

52. Sharykin A.S. Congenital heart disease. Guidelines for pediatricians, cardiologists, neonatologists. Moscow: Teremok. 2005:381. (In Russ.)

53. Favoccia C., Constantine A.H., Wort S.J., et al. Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease. Expert Review of Cardiovasc Therapy 2019; 17:449-59. https://doi.org/10.1080/14779072.2019.1623024

54. Baumgartner H., Bonhoeffer P., De Groot N.M., et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European Paediatric Cardiology (AEPC), ESC Committee for Practice Guidelines (CPG). Eur Heart J. 2010; 31(23):2915-57. https://doi.org/10.1093/eurheartj/ehq249

55. Heath D., Edwards J.E. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958; 4 (Part 1):533-47. https://doi.org/10.1161/01.CIR.18.4.533

56. Yamaki S., Horiuchi T., Miura M., et al. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest. 1986; 89(5):694-8. https://doi.org/10.1378/chest.89.5.694

57. Heath D., Helmholz H.F. Jr, Burchell H., et al. Relation between structural change in the small pulmonary arteries and the immediate reversibility of pulmonary hypertension following closure of ventricular and atrial septal defects. Circulation. 1958; 18(6):1167-74. https://doi.org/10.1161/01.cir.18.6.1167

58. Esipova I.K. Some questions in pulmonary pathology. The Academy of Sciences of the Soviet Union. 1962. (In Russ.)

59. Haworth S.G., Rabinovitch M. Pulmonary circulation. In: Anderson RH, Baker EJ, Penny DJ, Redington AN, Rigby ML, Wernovsky G (eds). Paediatric Cardiology, 3rd edn. Churchill Livingstone, Elsevier, Philadelphia, PA, 2010:117–141.

60. Rabinovitch M., Haworth S.G., Castaneda A.R., et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978; 58(6):1107-22. https://doi.org/10.1161/01.CIR.58.6.1107

61. Endo M., Yamaki S., Ohmi M., Tabayashi K. Pulmonary vascular changes induced by congenital obstruction of pulmonary venous return. Ann Thorac Surg. 2000; 69 (1):193-7. https://doi.org/10.1016/S0003-4975(99)01079-6

62. Dimopoulos K., Diller G.P., Opotowsky A.R., et al. Definition and Management of Segmental Pulmonary Hypertension. J Am Heart Assoc. 2018;7 (14):e008587. https://doi.org/10.1161/JAHA.118.008587

63. Thiene G., Frescura C., Bini R.M., et al. Histology of pulmonary arterial supply in pulmonary atresia with ventricular septal defect. Circulation. 1979; 60 (5):1066-74. https://doi.org/10.1161/01.cir.60.5.1066

64. Van Dissel A.C., Mulder B.J., Bouma B.J. The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. J of Clin Med. 2017; 6(4):40. https://doi.org/10.3390/jcm6040040

65. Gorbachevsky S.V., Shmalts A.A., Plotnikova L.R. Pulmonary hypertension in children with congenital heart disease. Moscow; OOO «Kedr», 2018; 91. (in Russ.)

66. Pulmonary hypertension in children. Editors L.A. Bockeria, S.V. Gorbachevsky, M.A. Shkolnikova. Moscow: Aktelion farmas’yutikalz, 2013; 416. (in Russ.)

67. Gorbachevsky S.V., Shmalts A.A. Hypertensive pulmonary vascular disease associated with congenital heart defects. In: L.A. Bockeria, K.V. Shatalov (eds.). Pediatric cardiac surgery. A guide for doctors. Moscow, 2016; 833–850. (in Russ.)

68. Hansmann G., Koestenberger M., Alastalo T.P., et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019; 38(9):879-901. https://doi.org/10.1016/j.healun.2019.06.022

69. Lammers A.E., Apitz C., Zartner P., et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2):ii1–13. https://doi.org/10.1136/heartjnl-2015-307792

70. Dimopoulos K., Diller G.P. Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017. 368p. https://doi.org/10.1007/978-3-319-46028-4

71. Dimopoulos K., Prapa M., Gatzoulis M. Eisenmenger syndrome and other types of pulmonary arterial hypertension related to congenital heart disease. In: Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer; 2013. https://doi.org/10.1007/978-1-4471-4619-3_182

72. Ikegami R., Ozaki K., Ozawa T., et al. Percutaneous Coronary Intervention for a Patient with Left Main Coronary Compression Syndrome. Intern Med. 2018; 57 (10):1421-4. https://doi.org/10.2169/internalmedicine.9534-17

73. Butera G., Mansour N.B., De Marco F. Emergency transcatheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4-year-old child. Catheter Cardiovasc Interv. 2019; 93(1):105-7. https://doi.org/10.1002/ccd.27796

74. Mamas M.A., Clarke B., Mahadevan V.S. Embolisation of systemic-to-pulmonary collaterals in patients with the Eisenmenger reaction presenting with haemoptysis. Cardiol Young. 2008; 18 (5):528-31. https://doi.org/10.1017/S1047951108002680

75. Larici A.R., Franchi P., Occhipinti M., et al. Diagnosis and management of hemoptysis. Diagn Interv Radiol. 2014; 20 (4):299-309. https://doi.org/10.5152/dir.2014.13426

76. Broberg C.S., Ujita M., Prasad S. et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007; 50(7):634–42. https://doi.org/10.1016/j.jacc.2007.04.056

77. Placik B., Rodbard S., McMahon J., Swaroop S. Pulmonary artery dissection and rupture in Eisenmenger’s syndrome. Vasc Surg. 1976; 10(2):72-80. https://doi.org/10.1177/153857447601000203

78. Areco D., Pizzano N. Pulmonary artery dissection: echocardiographic findings and diagnosis. Echocardiography. 2003; 20 (4): 375-7. https://doi.org/10.1046/j.1540-8175.2003.03044.x

79. Mikhail G.W., Gibbs J.S., Yacoub M.H. Pulmonary and systemic arterial pressure changes during syncope in primary pulmonary hypertension. Circulation. 2001; 104(11):1326-7. https://doi.org/10.1161/hc3601.095274

80. Moledina S., Hislop A.A., Foster H., et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart. 2010; 96(17):1401-6. https://doi.org/10.1136/hrt.2009.182378

81. Chazova I.E., Avdeev S.N., Tsareva N.A., et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskii arkhiv. 2014; 9:4-23. (In Russ.)

82. Kaemmerrer H., Koichiro N., Oechslin E., et al. Pulmonary Arterial Hypertension in Congenital Heart Disease: Eisenmenger’s Syndrome – A Global Perspectiv. 1st edition. Bremen: UNI-MED; 2013.

83. Oechslin E., Mebus S., Schulze-Neick I., et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. Cur Cardiol Rev. 2010; 6 (4):363–72. https://doi.org/10.2174/157340310793566127

84. Labombarda F., Kerros H., Grollier G. Eisenmenger syndrome due to a large ductus arteriosus. Arch Cardiovasc Dis. 2010; 103 (11-12):623-5. https://doi.org/10.1016/j.acvd.2010.02.004

85. Dimopoulos K. Eisenmenger syndrome in an adult patient with a large patent ductus arteriosus. Eur Respir Rev. 2013; 22(130): 558-64. https://doi.org/10.1183/09059180.00007013

86. Ryabykina G.V., Blinova E.V., Sakhnova T.A. Electrovectorcardiographic diagnosis of right ventricular hypertrophy in patients with pulmonary hypertension. Practitioners’ manual. Medical alphabet. 2017;1(8):52-66. (In Russ.)

87. Kamphuis V.P., Haeck M.L., Wagner G.S., et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol. 2014; 47(2):175-82. https://doi.org/10.1016/j.jelectrocard.2013.10.010

88. Tongers J., Schwerdtfeger B., Klein G., et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007; 153:127-32. https://doi.org/10.1016/j.ahj.2006.09.008

89. Yurpol’skaya L.A., Shmalts A.A. Х-ray methods and magnetic resonance imaging in pulmonary hypertension associated with congenital heart disease. Children’s Heart and Vascular Diseases. 2021;18 (2):83–93 (in Russ.) https://doi.org/10.24022/1810-0686-2021-18-2-83-93

90. Tsallagova Z.S., Lazutkina V.K. Possibilities of radiography in assessment of pulmonary arterial hypertension. Meditsinskaya vizualizatsiya. 2001; (4):58–63. (In Russ.)

91. X-ray diagnostics of diseases of the heart and blood vessels. /Ed. M.A. Ivanitskaya. -M., “Medicine”, 1970. (In Russ).

92. X-ray diagnostics in pediatrics. Guide for doctors in 2 volumes. / Ed. V.F.Baklanova, M.A.Filippkina.-M.: Medicine, -1988.-V.1.-448 P. (In Russ).

93. Pediatric cardiology. Ed. J. Hoffman. Translation from English -M .: Practice. -2006.-543P. (In Russ.)

94. Korobkova I.K., Lazutkina V.K., Nizovtsova L.A., Riden T.V. Radiographic assessment of pulmonary hypertension: Methodical aspects. Journal of radiology and nuclear medicine. 2015;(4):46-53. (In Russ.) https://doi.org/10.20862/0042-4676-2015-0-4-14-21

95. Dimopoulos K., Giannakoulas G., Bendayan I., et al. Cardiothoracic ratio from postero-anterior chest radiographs: a simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease. Int J Cardiol. 2013.166:453-7. https://doi.org/10.1016/j.ijcard.2011.10.125

96. Freedom R.M., Yoo Shi-joon, Mikailian H., Williams W.G. The Natural and Modified History of Congenital Heart Disease. 2008. Wiley-Blackwell-904 p. https://doi.org/10.1002/9780470986905.ch1

97. Freedom R. M., Benson L.N., Smallhorn J.F. Neonatal Heart Disease. Springer-Verlag London 1992, 881p. https://doi.org/10.1007/978-1-4471-1814-5

98. Koestenberger M., Apitz C., Abdul-Khaliq H., Hansmann G. Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and D6PK. Heart. 2016; 102 (Suppl 2): ii14-22. https://doi.org/10.1136/heartjnl-2014-307200

99. Anderson R.H., Baker E.J., Penny D.J., et al. Paediatric cardiology. 3d edition. Elsevier, 2009.

100. Baryshnikova I.Yu., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Russian Bulletin of Perinatology and Pediatrics. 2021; 66(6):23–32 (In Russ). https://doi.org/10.21508/1027-4065-2021-66-6-23-32

101. Li W., West C., McGhie J., et al. Consensus recommendations for echocardiography in adults with congenital heart defects from the International Society of Adult Congenital Heart Disease (ISACHD). Int J Cardiol. 2018; 272:77-83. https://doi.org/10.1016/j.ijcard.2018.07.058

102. Augustine D.X., Coates-Bradshaw L.D., Willis J., et al. BSE pulmonary hypertension guideline 2018; 5 (3): G11–G24. https://doi.org/10.1530/ERP-17-0071

103. Rudski LG., Lai W.W., Afi lalo J., et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23: 685-713. https://doi.org/10.1016/j.echo.2010.05.010

104. Zaidi A., Knight D.S., Augustine D.X., et al. Echocardiographic assessment of the right heart in adults: a practical guideline from the British Society of Echocardiography. 2020; 7 (1): G19–G41. https://doi.org/10.1530/ERP-19-0051

105. Amsallem M., Sternbach J.M., Adigopula S., et al. Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr. 2016; 29: 93–102. https://doi.org/10.1016/j.echo.2015.11.001

106. Fisher M.R., Forfia P.R., Chamera E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 (7): 615-21. https://doi.org/10.1164/rccm.200811-1691OC

107. Rimington H., Chambers J.B. Echocardiography: a practical guide for reporting and interpretation. Third edition. CRC Press; 2016. https://doi.org/10.1201/b19334

108. Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Society of Echocardiography. 2015; 28 (1): 1–39. https://doi.org/10.1016/j.echo.2014.10.003

109. Abraham S., Weismann C.G. Left ventricular end-systolic eccentricity index for assessment of pulmonary hypertension in infants. Echocardiography. 2016; 33: 910–15. https://doi.org/10.1111/echo.13171

110. Nagueh S.F., Smiseth O.A., Appleton C.P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29:277-314. https://doi.org/10.1016/j.echo.2016.01.011

111. Friedberg M., Merten L. Tissue velocities, strain, and strain rate for echocardiographic assessment of ventricular function in congenital heart disease. European J Echocardiography. 2009; 10: 585-93. https://doi.org/10.1093/ejechocard/jep045

112. Lai W.W., Mertens L.L., Cohen M.S., Geva T. Echocardiography in pediatric and congenital heart disease. From Fetus to Adult. Second Edition. Wiley Blackwell; 2016.

113. Moceri P., Li W., Dimopoulos K. Echocardiography in the Diagnosis and Follow-Up of Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017. https://doi.org/10.1007/978-3-319-46028-4_11

114. Bokeriya L.A., Baryshnikova I.Yu., Gorbachevsky S.V. Echocardiography in the diagnosis and assessment of pulmonary hypertension. Tutorial. Moscow, 2017; 54 р. (In Russ.)

115. Mertens L., Friedberg M.K. Systolic ventricular function. In: Echocardiography in Pediatric and Congenital Heart Disease: From Fetus to Adult; 2016, Hoboken, US: Wiley-Blackwell, p.96-131.

116. Gurudevan S.V., Malouf P.J., Kahn A.M., et al. Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. J Am Soc Echocardiogr. 2007; 20 (10):1167–71. https://doi.org/10.1016/j.echo.2007.02.004

117. Sutherland G.R., Di Salvo G., Claus P., et al. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr 2004; 17: 788-802. https://doi.org/10.1016/j.echo.2004.03.027

118. D’Alto M., Dimopoulos K., Budts W., et al. Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension. Heart. 2016; 102 (12): 910-18. https://doi.org/10.1136/heartjnl-2015-308903

119. Puchalski M.D., Lui G.K., Miller-Hance W., et al. Guidelines for Performing a Comprehensive Transesophageal Echocardiographic. Journal of the American Society of Echocardiography. 2019; 32 (2): 173–215. https://doi.org/10.1016/j.echo.2018.08.016

120. Shariya A.M., Martynyuk T.V., Ternovoy S.K., Shariya M.A. Possibilities of Magnetic Resonance Tomography in Diagnosis of Pulmonary Arterial Hypertension. Kardiologiia. 2021;61(6):97-104. (In Russ.) https://doi.org/10.18087/cardio.2021.6.n1185

121. L.A. Bockeria, V.N. Makarenko, L.A. Yurpol’skaya. Computer tomography and magnetic resonance imaging in the diagnostic algorithm of congenital heart disease: what, when, who? – “for” and “against”. Russian Journal of Thoracic and Cardiovascular Surgery. 2014; 3: 4-13. (In Russ.)

122. Latus H., Kuehne T., Beerbaum Ph., et all. Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/ pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102: ii30–ii35. https://doi.org/10.1136/heartjnl-2015-308246

123. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007. 28:1250-7. https://doi.org/10.1093/eurheartj/ehl477

124. Belokon N.A., Podzolkov V.P., Mitrofanov I.O. Congenital heart disease .-M .: Medicine .-1990.-352p. (In Russ).

125. Brignole M., Auricchio A., Baron-Esquivias G., et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013; 34: 2281-329. https://doi.org/10.1093/europace/eut206

126. Radenkovic D., Weingärtner S., Ricketts L., et al. T1 mapping in cardiac MRI. Heart Fail Rev. 2017; 22:415–430. https://doi.org/10.1007/s10741-017-9627-2

127. Salerno M., Sharif B., Arheden H., et al. Recent Advances in Cardiovascular Magnetic Resonance Techniques and Applications. Cir.cCardiovasc.Imaging. 2017; 10 :e003951. https://doi.org/10.1161/CIRCIMAGING.116.003951

128. European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://https://www.ema.europa.eu/en/documents/press-release/emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents-body-scans_en.pdf

129. Odagiri K., Inui N., Hakamata A., et al. Noninvasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. Springer Plus 2016; 5: 1071. https://doi.org/10.1186/s40064-016-2755-7

130. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 2007; 28: 1187-1189. https://doi.org/10.1093/eurheartj/ehm074

131. Perloff J.K., Marelli A. Perloff’s Clinical Recognition of Congenital Heart Disease: Expert Consult Online and Print, 6e. 6th edition. Philadelphia: Saunders; 2012.

132. de Siqueira M.E.M.., Pozo E., Fernandes V.R., et all. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J of Cardiovasc Magn Res-2016; https://doi.org/10.1186/s12968-016-0258-x

133. Tello K., Dalmer A., Vanderpool R., et al. Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC Cardiovasc Imaging. 2019; 12 (1): 2155-64. https://doi.org/10.1016/j.jcmg.2018.12.032

134. X-ray diagnostics of diseases of the heart and blood vessels. Ed. M.A. Ivanitskaya. M., “Medicine”, 1970 (In Russ).

135. Makarenko V.N., Yurpolskaya L.A., Zelenikin M.M., Shinkareva T.V. Computed tomography in the evaluation of patients after Fontan surgery. Bulletin of the NCSSH them. A.N. Bakulev RAMS. 2010; 11(1):46-50. (In Russ).

136. Kilner P., Nichol E., Rubens M. The roles of CT and CMR in Adult Congenital Heart Disease. In: ESC Textbook of Cardiovascular Imaging. 2nd ed, Oxford:Oxford University Press; 2015, p. 563-600.

137. Grosse-Wortmann L., Drolet Chr., Dragulescu An., et al. Aortopulmonary collateral flow volume affects early postoperative outcome after Fontan completion: A multimodality study. J. Thorac. Cardiovasc. Surg. 2012; 144:1329-36. https://doi.org/10.1016/j.jtcvs.2012.03.032

138. Habib G., Lancellotti P., Antunes M.J., et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36:3075-3128. https://doi.org/10.1093/eurheartj/ehv319

139. Ohno Y., Koyama H., Lee H.Y., Miura S.t all. Contrast-enhanced CT-and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagn Interv Radiol-2016; 22: 407–421. https://doi.org/10.5152/dir.2016.16123

140. Pienn M., Kovacs G., Tscherner M., Avian A. et all. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study. Eur Radiol.-2014; 24:668–676. https://doi.org/10.1007/s00330-013-3067-8

141. Sobolev A.V., Shmalts A.A. Endovascular diagnostics of pulmonary hypertension associated with congenital heart defects. Part 1. Cardiac catheterization and angiography. Russian journal of endovascular surgery. 2021; 8(3):263–71. (In Russ.) https://doi.org/10.24183/2409-4080-2021-8-3-263-271

142. Guillinta P., Peterson K.L., Ben-Yehuda O. Cardiac catheterization techniques in pulmonary hypertension. Cardiol Clin. 2004; 22: 401–15. https://doi.org/10.1016/j.ccl.2004.04.011

143. Peterson K.L., Nicod P. Cardiac catheterization: methods, diagnosis, and therapy. Saunders, Philadelphia; 1997.

144. Barnett C., Ben-Yehuda О. Cardiac Catheterization in the Patient with Pulmonary Hypertension. Textbook of Pulmonary Vascular Disease Springer, Science+Business Media, LLC; 2011. https://doi.org/10.1007/978-0-387-87429-6

145. Gorbachevsky S.V., Belkina M.V., Koledinsky D.G., et al. Invasive pulmonary artery pressure monitoring is an objective method for assessing the severity of pulmonary hypertension in children with congenital heart disease. Children’s diseases of the heart and blood vessels. 2006; 4:77–81. (In Russ).

146. Wilkinson J.L. The Fontan сirculation. Results, late Follow-up and management. Heart Views. 2004; 4 (4): 73-78.

147. Fredenburg T.B., Johnson T.R., Cohen M.D. The Fontan Procedure: Anatomy, Complications, and Manifestations of Failure. RadioGraphics. 2011;31(2): 453–463. https://doi.org/10.1148/rg.312105027

148. Bergersen L., Foerster S., Marshall A.C., Meadows J. (eds). Congenital heart disease: the catheterization manual. Springer, New York; 2009. https://doi.org/10.1007/978-0-387-77292-9

149. Бокерия Л.А., Алекян Б.Г. (ред.). Руководство по рентгеноэндоваскулярной хирургии сердца и сосудов. Москва, НЦССХ им. А.Н. Бакулева РАМН; 2008.

150. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111:3105–11. https://doi.org/10.1161/CIRCULATIONAHA.104.488486

151. Barst R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986; 89:497–503. https://doi.org/10.1378/chest.89.4.497

152. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327:76–81. https://doi.org/10.1056/NEJM199207093270203

153. Douwes J.M., van Loon RLE, Hoendermis E.S, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011; 32(24):3137-46. https://doi.org/10.1093/eurheartj/ehr282

154. Chessa M. Cardiac Catheterization. In: Dimopoulos K, Diller G.P. (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

155. Hoeper M.M., Lee S.H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006; 48:2546–52. https://doi.org/10.1016/j.jacc.2006.07.061

156. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: Comparative severity, correlates, and prognostic implication. Circulation. 2005. 112:828–35. https://doi.org/10.1161/CIRCULATIONAHA.104.529800.

157. Savarese G., Paolillo S., Costanzo P., et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? А meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60:1192–1201. https://doi.org/10.1016/j.jacc.2012.01.083

158. Gabler N.B., French B., Strom B.L, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126: 349–56. https://doi.org/10.1161/CIRCULATIONAHA.112.105890

159. Glushko L.A., Shmalts A.A. Assessment of the state of the cardiorespiratory system in pulmonary hypertension associated with congenital heart disease. Creative cardiology. 2021; 15(2): 167-179. (In Russ).

160. Arena R., Lavie C.J., Milani R.V., et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010; 29 (2): 159-73. https://doi.org/10.1016/j.healun.2009.09.003

161. Johnson M.K., Thompson S. The role of exercise testing in the modern management of pulmonary arterial hypertension. Diseases. 2014; 2: 120-47. https://doi.org/10.3390/diseases2020120

162. Wasserman K., Hansen J.E., Sue D.Y., et al. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. Fifth edition. Philadelphia: Lippincott Williams & Wilkins; 2012, 572 p.

163. Seeger W., Adir Y., Barbera J.A., et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62: D109–16. https://doi.org/10.1016/j.jacc.2013.10.036

164. Johnson J.T., Yetman A.T. Cardiopulmonary exercise testing in adults with congenital heart disease. Prog Pediatr Cardiol. 2012; 34: 47–52.

165. Laveneziana P., Garcia G., Joureau B. et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J. 2013. 41:578-587. https://doi.org/10.1183/09031936.00223611

166. Ferrazza A.M., Martolini D., Valli G., Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009; 77 (1): 3-17. https://doi.org/10.1159/000186694

167. Mantegazza V., Apostolo A, Hager A. Cardiopulmonary Exercise Testing in Adult Congenital Heart Disease. Ann Am Thorac Soc. 2017; 14 (Suppl.1): S93-S101. https://doi.org/10.1513/AnnalsATS.201611-876FR

168. Diller G.P., Kempny A., Inuzuka R., et al. Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart. 2014; 100(17): 1366-72. https://doi.org/10.1136/heartjnl-2014-305690

169. Buys R., Cornelissen V., Van De Bruaene A., et al. Measures of exercise capacity in adults with congenital heart disease. Int J Cardiol. 2011; 153 (1): 26-30. https://doi.org/10.1016/j.ijcard.2010.08.030

170. Taran I.N., Valieva Z.S., Martynyuk T.V., et al. Spiroveloergometry in risk stratification of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eurasian Cardiology Journal. 2017; 4:86-92. (In Russ). https://doi.org/10.38109/2225-1685-2017-4-86-92

171. Zhao Q.H., Wang L., Pudasaini B., et al. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension. Clin Cardiol. 2017; 40 (2): 95-101. https://doi.org/10.1002/clc.22635

172. Chazova I.E., Martynyuk T.V. et al. Diagnosis and treatment of pulmonary hypertension. Russian recommendations. Cardiovascular Therapy and Prevention 2007; 6: Appendix 2. (In Russ).

173. Sun X.G., Hansen J.E., Oudiz R.J, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41:1028–35. https://doi.org/10.1016/s0735-1097(02)02964-9

174. Alonso-Gonzalez R., Borgia F., Diller G.P., et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. 2013; 127 (8): 882-90. https://doi.org/10.1161/CIRCULATIONAHA.112.126755

175. Ferguson G.T., Enright P.L., Buist A.S., Higgins M.W. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest. 2000;117 (4): 1146-61. https://doi.org/10.1378/chest.117.4.1146

176. Arkhipova O.A., Martynyuk T.V., Samoilenko L.E., et al. Perfusion lung scintigraphy in patients with pulmonary hypertension of various etiologies. Eurasian Cardiology Journal. 2015; 4:21-25. (In Russ).

177. Tunariu N., Gibbs S.R., Win Z., et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007; 48: 680-84. https://doi.org/10.2967/jnumed.106.039438

178. Albrecht T., Blomley M.J., Cosgrove D.O., et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353: 1579-83. https://doi.org/10.1016/S0140-6736(98)06373-9

179. Perloff J.K. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993; 11: 689-99.

180. Giannakoulas G., Mouratoglou S., Gatzoulis M.A.. et al. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. International Journal of Cardiology. 2014; 174 (3): 618–23. https://doi.org/10.1016/j.ijcard.2014.04.156

181. Fenster B.E., Lasalvia L, Schroeder J.D., et al. Cystatin C for pulmonary hypertension. Respirology. 2014. 19: 583-89. https://doi.org/10.1111/resp.12259

182. Scognamiglio G., Kempny A., Price L.C., et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart. 2014. 100:1335-1341. https://doi.org/10.1136/heartjnl-2014-305494

183. Dimopoulos K., Okonko D.O., Diller G.P., et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006; 113 (24): 2796-802. https://doi.org/10.1161/CIRCULATIONAHA.105.594218

184. Deanfield J., Thaulow E., Warnes C., et al. Management of grown-up congenital heart disease. Eur Heart J. 2003; 24: 1035-84. https://doi.org/10.1016/s0195-668x(03)00131-3

185. Yang-Ting S., Aboulhosn J., Sun X.G. et al. Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome. Congenit Heart Dis. 2011; 6 (2): 139-46.

186. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121: 20-25. https://doi.org/10.1161/CIRCULATIONAHA.109.883876

187. Diller G.P., Korten M.A., Bauer U.M., et al. German Competence Network for Congenital Heart Defects Investigators. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J 2016; 37: 14491455. https://doi.org/10.1093/eurheartj/ehv743

188. Oster M., Bhatt A., Zaragoza-Macias E., et al. Interventional therapy versus medical therapy for secundum atrial septal defect: a systematic review (part 2) for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e000–000. https://doi.org/10.1161/CIR.0000000000000605

189. Shah D., Azhar M., Oakley C.M., et al. Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J. 1994; 71: 224–27. https://doi.org/10.1136/hrt.71.3.224

190. Cho Y.H., Jun T-G., Yang J-H., et al. Surgical strategy in patients with atrial septal defect and severe pulmonary hypertension. Heart Surg Forum. 2012; 15:E111–5. S4.1.1-21.

191. Kouchoukos N.T., Blackstone E.H., Kirklin J.W. Surgical implications of pulmonary hypertension in congenital heart disease. Adv Cardiol. 1978: S4: 225–31. https://doi.org/10.1159/000401033

192. Yan C., Zhao S., Jiang S., et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007; 93: 514–18. https://doi.org/10.1136/hrt.2006.091215

193. Gamboa R., Rios-Méndez R.E., Mollón F.P., et al. Percutaneous closure of patent ductus arteriosus in adults using different devices. Rev Esp Cardiol. 2010; 63: 726–29. https://doi.org/10.1016/s1885-5857(10)70147-x

194. Jeong Y-H., Yun T-J., Song J-M., et al. Left ventricular remodeling and change of systolic function after closure of patent ductus arteriosus in adults: device and surgical closure. Am Heart J. 2007; 154: 436–40. https://doi.org/10.1016/j.ahj.2007.04.045

195. Zabal C., García-Montes J.A., Buendía-Hernández A., et al. Percutaneous closure of hypertensive ductus arteriosus. Heart. 2010; 96: 625–29. https://doi.org/10.1136/hrt.2009.185025

196. Lim D.S., Forbes T.J., Rothman A., et al. Transcatheter closure of high-risk muscular ventricular septal defects with the CardioSEAL occluder: initial report from the CardioSEAL VSD registry. Catheter Cardiovasc Interv. 2007; 70 (5): 740-44

197. Chessa M., Butera G., Negura D., et al. Transcatheter closure of congenital ventricular septal defects in adult: mid-term results and complications. Int J Cardiol. 2009; 133 (1):70-3. https://doi.org/10.1016/j.ijcard.2007.11.098

198. Gorbachevsky S.V., Shmalts A.A. Palliative atrial and arterial switching in transposition of the main arteries with ventricular septal defect and severe pulmonary vascular disease. Children’s diseases of the heart and blood vessels. 2019; 16(2): 86-94. (In Russ).

199. Petrosyan K.V., Gorbachevsky S.V., Dadabaev G.M., Pardaev D.B. Stenting of the trunk of the left coronary artery in a patient with pulmonary hypertension. Eurasian Cardiology Journal. 2017; 3:86-87.(In Russ).

200. Gorbachevsky S.V., Shmalts A.A., Dadabaev G.M., et al. Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics (Basel). 2020; 10(9): 725. https://doi.org/10.3390/diagnostics10090725

201. Gorbachevsky S.V., Pursanov M.G., Shmalts A.A., et al. Results of atrioseptostomy with stenting in patients with idiopathic and similar forms of pulmonary arterial hypertension. Thoracic and cardiovascular surgery. 2019; 61(2): 100-113..(In Russ).

202. Shmalts A.A., Nishonov N.A. Atrioseptostomy in patients with pulmonary hypertension. Thoracic and cardiovascular surgery. 2015; 57(5): 18-25.(In Russ).

203. Christie J.D., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult lung and heart-lung transplant report 2012. J. Heart Lung Transplant. 2012; 31:1073–86. https://doi.org/10.1016/j.healun.2012.08.004

204. Fadel E., Mercier O., Mussot S., et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg. 2010; 38: 277– 84. https://doi.org/10.1016/j.ejcts.2010.02.039

205. Hopkins W.E., Ochoa L.L., Richardson G.W., et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996; 15 (1):100-5.

206. Moons P., De Geest S., Budts W. Comprehensive care for adults with congenital heart disease: expanding roles for nurses. Eur J Cardiovasc Nurs. 2002; 1: 23-28. https://doi.org/10.1016/S1474-5151(01)00014-7

207. Baumgartner H., Budts W., Chessa M., et al, Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. Recommendations for organization of care for adults with congenital heart disease and for training in the subspecialty of ‘Grown-up Congenital Heart Disease’ in Europe: a position paper of the Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. Eur Heart J. 2014; 35: 686-90. https://doi.org/10.1093/eurheartj/ehaa554

208. Thomet C., Moons P., Budts W., et al. ESC Working Group on Grown-up Congenital Heart Disease. Staffing, activities, and infrastructure in 96 specialised adult congenital heart disease clinics in Europe. Int J Cardiol 2019; 292: 100-105. https://doi.org/10.1016/j.ijcard.2019.04.077

209. Popelová J., Oechslin E., Kaemmerer H., Sutton M. Congenital Heart Disease in Adults 2008 Informa UK Ltd.-183p. https://doi.org/10.3109/9780203091685

210. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J., et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39: 31653241. https://doi.org/10.1093/eurheartj/ehy340

211. Sliwa K., van Hagen I.M., Budts W., et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016; 18 (9): 1119–28. https://doi.org/10.1002/ejhf.594

212. Jaı ̈s X., Olsson K.M, Barbera J.A., et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012; 40: 881–85. https://doi.org/10.1183/09031936.00141211

213. Kovacs A.H., Sears S.F., Saidi A.S. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. Am Heart J 2005; 150: 193-201. https://doi.org/10.1016/j.ahj.2004.08.025

214. Raines D.E., Liberthson R.R., Murray J.R. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger’s physiology. J Clin Anesth. 1996; 8: 341–47. https://doi.org/10.1016/0952-8180(96)00084-0

215. Grünig, E., Benjamin, N., Krüger, U., et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:30-36. https://doi.org/10.1016/j.ijcard.2018.08.085

216. Blanche C., Alonso-Gonzalez R., Uribarri A. et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol. 2018. 267:79-83. https://doi.org/10.1016/j.ijcard.2018.05.062

217. Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 577. https://doi.org/10.1016/s0002-9343(01)00915-9

218. Olsson K.M., Delcroix M., Ghofrani H.A., et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014; 129: 57–65. https://doi.org/10.1161/CIRCULATIONAHA.113.004526

219. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962. 219. https://doi.org/10.1093/eurheartj/ehw210

220. Steffel J., Verhamme P, Potpara T.S., et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39:1330-93. https://doi.org/10.1093/eurheartj/ehy136

221. Pujol C., Niesert A.C., Engelhardt A., et al. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol. 2016; 117: 450-55. https://doi.org/10.1016/j.amjcard.2015.10.062

222. Yang H., Bouma B.J., Dimopoulos K., et al. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol. 2019; 299: 123-30. https://doi.org/10.1016/j.ijcard.2019.06.014

223. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001; 164:1682–87. https://doi.org/10.1164/ajrccm.164.9.2106076

224. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985; 131: 493-98. https://doi.org/10.1164/arrd.1985.131.4.493

225. van de Veerdonk M.C., Kind T., Marcus J.T., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011; 58: 2511-19. https://doi.org/10.1016/j.jacc.2011.06.068

226. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998; 114: 787-92. https://doi.org/10.1378/chest.114.3.787

227. Arkhipova O.A., Martynyuk T.V., Chazova I.Y. Tactics features of conducting and choosing specific therapy for adult patients with pulmonary arterial hypertension associated with congenital heart disease. Eurasian heart journal. 2018;(1):48-59. (In Russ.) https://doi.org/10.38109/2225-1685-2018-1-48-53

228. Shmalts A.A., Gorbachevskiy S.V.. Evidence base for specific pulmonary vasodilators in children with congenital heart defects. Pediatrics named after G.N. Speransky. 2017; 96 (6): 126-139. (In Russ.) https://doi.org/10.24110/0031-403X-2017-96-6-126-139

229. Shmalts AA, Gorbachevsky SV. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93(9):1106–1116. (In Russ.) https://doi.org/10.26442/00403660.2021.09.201022

230. Shmal’ts A.A., Belkina M.V., Gorbachevskiy S.V. Specific pulmonary vasodilators after Fontan operation. Detskie bolezni serdtsa i sosudov (Children’s Heart and Vascular Diseases). 2017; 14 (1): 16–24 (in Russ.) https://doi.org/10.24022/1810-0686-2017-14-1-16-24

231. Tracleer®. Instructions for use of a medicinal product for medical use. LS-002509 (In Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=93619b5d-c8c6-4bdb-b201-88aff22c785c&t=

232. Bosenex. Instructions for medical use of the use of the medical product. LP-004208 (In Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=68d79ec9-1045-403c-be20-e88cc33f0aa6&t=

233. Opsumit®. Instructions for use of a medicinal product for medical use. LP-003310. (In Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2c51f9d-696d-4b23-881a-8c8d0fec4b96&t=

234. Upbravi. Instructions for use of a medicinal product for medical use. LP-005577. (In Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=094dda8d-ba79-4353-83f9-98ea68b865aa&t=

235. Manes A. PAH in Patients with Prevalent Systemic–Pulmonary Shunts and PAH in Patients with Small Cardiac Defects. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017

236. Idorn L., Sondergaard L. Pulmonary Vascular Disease in Patients with Fontan-Type Circulation. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

237. Moledina Sh., Theocharis P. Pulmonary Arterial Hypertension in Patients with Previous Reparative Surgery. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

238. Shmalts A.A., Gorbachevsky S.V. Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia. Therapeutic Archive. 2020; 92 (12). (In Russ.) https://doi.org/10.26442/00403660.2020.12.000840

239. D’Alto M., Diller G.P. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014; 100 (17):1322-28. https://doi.org/10.1136/heartjnl-2014-305574

240. Chazova I.E., Martynyuk T.V., Nakonechnikov S.N. Endothelin receptor antagonists in pulmonary arterial hypertension: yesterday, today and tomorrow. Russian Journal of Cardiology 2009; 4:73–81. (In Russ.)

241. Galie N., Manes A., Palazzini M., et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008. 68:1049–66. https://doi.org/10.2165/00003495-200868080-00004

242. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896–903. https://doi.org/10.1056/NEJMoa012212

243. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 (1): 48–54. https://doi.org/10.1161/CIRCULATIONAHA.106.630715

244. Gatzoulis M.A., Beghetti M., Galie N., et al. Long-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008; 127 (1): 27-32. https://doi.org/10.1016/j.ijcard.2007.04.078

245. Galiè N., Rubi.n L., Hoeper M., et al. Treatment of patients with symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 (9630): 2093-100. https://doi.org/10.1016/S0140-6736(08)60919-8

246. Sitbon O., Beghetti M., Petit J., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest. 2006; 36 Suppl 3: 25-31. https://doi.org/10.1111/j.1365-2362.2006.01685.x

247. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest. 2006; 129 (4):1009-15. https://doi.org/10.1378/chest.129.4.1009

248. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007; 93 (8): 974-76. https://doi.org/10.1136/hrt.2006.089185

249. Durongpisitkul K., Jakrapanichakul D., Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. J Med Assoc Thai. 2008; 91 (2): 196-202.

250. Duffels M.G., Vis J.C., van Loon R.L, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009; 103 (9): 1309-15. https://doi.org/10.1016/j.amjcard.2009.01.021

251. Vis J.C., Duffels M.G., Mulder P., et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013; 164 (1): 64-9. https://doi.org/10.1016/j.ijcard.2011.06.064

252. Baptista R, Castro .G, da Silva A.M., et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013; 32 (2): 123-29. https://doi.org/10.1016/j.repc.2012.02.023

253. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809– 818. https://doi.org/10.1056/NEJMoa1213917

254. Gatzoulis M.A., Landzberg M., Beghetti M., et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019; 139(1):51-63. https://doi.org/10.1161/CIRCULATIONAHA.118.033575

255. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 :2148–57. https://doi.org/10.1056/NEJMoa050010

256. Lu X.L., Xiong C.M., Shan G.L., et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010; 28 (6): 350-55. https://doi.org/10.1111/j.1755-5922.2010.00213.x

257. Chau E.M., Fan K.Y., Chow W.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120 (3): 301-5. https://doi.org/10.1016/j.ijcard.2006.10.018

258. Zeng W.J., Lu X.L, Xiong C.M., et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol. 2011; 34 (8): 513-18. https://doi.org/10.1002/clc.20917

259. Iversen K., Jensen A.S., Jensen T.V., et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 31 (9):1124-31. https://doi.org/10.1093/eurheartj/ehq011

260. Ghofrani H. A., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4): 330-40. https://doi.org/10.1056/NEJMoa1209655

261. Shmal’ts A.A., Gorbachevskiy S.V. Riociguat and sildenafil for pulmonary hypertension: similarity and difference. PULMONOLOGIYA. 2016;26(1):85-91. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-1-85-91

262. Valieva Z.S., Gratsianskaya S.E., Martynyuk T.V. The soluble guanylate cyclase stimulator riociguat is the first-line therapy for chronic thromboembolic pulmonary hypertension patients. Kardiologiia. 2020;60(8):115-123. (In Russ.) https://doi.org/10.18087/cardio.2020.8.n1198

263. Stasch J.P., Pacher P., Evgenov O.V. Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation 2011; 123: 2263-2274. https://doi.org/10.1161/CIRCULATIONAHA.110.981738

264. Rubin L.J., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015; 45 (5): 1303-13. https://doi.org/10.1183/09031936.00090614

265. Rosenkranz S., Ghofrani H.A., Beghetti M., et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101 (22): 1792-99. https://doi.org/10.1136/heartjnl-2015-307832

266. Cha K.S., Cho K.I., Seo J.S., et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013; 112 (11):1834-39. https://doi.org/10.1016/j.amjcard.2013.08.003

267. Chon M.K., Cho K.I., Cha K.S., et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome. J Cardiol. 2017; 69 (5):741-46. https://doi.org/10.1016/j.jjcc.2016.07.002

268. Sitbon O., Channick R., Chin K.M., et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. https://doi.org/10.1056/NEJMoa1503184

269. Beghetti M., Channick R.N., Chin K.M., et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019; 21 (3): 352-59. https://doi.org/10.1002/ejhf.1375

270. Hascoet S, Fournier E, Jaïs X., et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Arch Cardiovasc Dis. 2017;110(5):303-316 https://doi.org/10.1016/j.acvd.2017.01.006

271. Li Q., Kuang H.Y., Wu Y.H., et al. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(20):e15632. https://doi.org/10.1097/MD.0000000000015632

272. D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012; 155 (3):378-82. https://doi.org/10.1016/j.ijcard.2010.10.051

273. Varela D.L., Teleb M., El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart. 2018; 5(1):e000744. https://doi.org/10.1136/openhrt-2017-000744

274. Brida M., Gatzoulis M.A. Pulmonary arterial hypertension in adult congenital heart disease. Heart. 2018; 104 (19): 1568-74. https://doi.org/10.1136/heartjnl-2017-312106

275. Schuuring M.J., Bouma B.J., Cordina R., et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol. 2013; 164 (1): 106-10. https://doi.org/10.1016/j.ijcard.2011.06.084

276. Hebert A, Mikkelsen UR, Thilen U, et al., Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014; 130(23):2021-30. https://doi.org/10.1161/CIRCULATIONAHA.113.008441

277. Agnoletti G., Gala S., Ferroni F., et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg. 2017; 153 (6): 1468-75. https://doi.org/10.1016/j.jtcvs.2017.01.051

278. Schuuring M.J., Vis J.C., van Dijk A.P., et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013; 15 (6): 690-98. https://doi.org/10.1093/eurjhf/hft017

279. Giardini A., Balducci A., Specchia S., et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008; 29 (13): 1681-87. https://doi.org/10.1093/eurheartj/ehn215

280. Van De Bruaene A., La Gerche A., et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging. 2014; 7 (2): 265-73. https://doi.org/10.1161/CIRCIMAGING.113.001243

281. Blok I.M., van Riel A.C.M.J., van Dijk A.P.J., et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol. 2017; 227: 51-52. https://doi.org/10.1016/j.ijcard.2016.11.211

282. Gelatt M., Hamilton R.M., et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997; 29: 194-201. https://doi.org/10.1016/s0735-1097(96)00424-x

283. Dearani J.A., Danielson G.K., Puga F.J., et al. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg. 2003;75:399-410. https://doi.org/10.1016/s0003-4975(02)04547-2

284. Giannakoulas G., Gatzoulis M.A. Pulmonary arterial hypertension in congenital heart disease: current perspectives and future challenges. Hellenic J Cardiol 2016; 57:218-22. https://doi.org/10.1016/j.hjc.2016.05.002

285. Van De Bruaene A., Toh N., et al. Pulmonary hypertension in patients with a subaortic right ventricle: prevalence, impact and management. Heart 2019;105:1471-78. https://doi.org/10.1136/heartjnl-2019-314756

286. De Pasquale G., Bonassin Tempesta F, Lopes BS, et al. High prevalence of baffle leaks in adults after atrial switch operations for transposition of the great arteries. Eur Heart J Cardiovasc Imaging. 2017; 18: 531-35. https://doi.org/10.1093/ehjci/jew276

287. Rydman R., Gatzoulis M.A., Ho S.Y., et al. Systemic right ventricular fibrosis detected by cardiovascular magnetic resonance is associated with clinical outcome, mainly new-onset atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great arteries. Circ Cardiovasc Imaging. 2015; 8: e002628. https://doi.org/10.1161/CIRCIMAGING.114.002628

288. Zaragoza-Macias E., Zaidi A.N., Dendukuri N., Marelli A. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73: 1564-78. https://doi.org/10.1016/j.jacc.2018.08.1030

289. Voet A., Rega F., de Bruaene A.V., et al. Long-term outcome after treatment of isolated pulmonary valve stenosis. Int J Cardiol. 2012; 156: 11-15. https://doi.org/10.1016/j.ijcard.2010.10.038

290. Raissadati A., Nieminen H., Sairanen H., Jokinen E. Outcomes after the Mustard, Senning and arterial switch operation for treatment of transposition of the great arteries in Finland: a nationwide 4-decade perspective. Eur J Cardiothorac Surg. 2017; 52: 573-80. https://doi.org/10.1093/ejcts/ezx107

291. Hernandez-Madrid A., Paul T., Abrams D., et al. ESC Scientific Document Group. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital Heart Disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace. 2018; 20:1719-53. https://doi.org/10.1093/europace/eux380

292. Redington A.N., Somerville J. Stenting of aortopulmonary collaterals in complex pulmonary atresia. Circulation. 1996; 94: 2479-84. https://doi.org/10.1161/01.cir.94.10.2479.

293. Hsu C.H., Gomberg-Maitland M., Glassner C. et al. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl. 2011; 172: 6-14. https://doi.org/10.1111/j.1742-1241.2011.02711.x

294. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome. Factors relating to deterioration and death, Eur. Heart J. 1998; 19: 1845–55. https://doi.org/10.1053/euhj.1998.1046

295. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122

296. Baumgartner H., De Backer J., Babu-Naraya S.V., et al. 2020 ESC Guidelines for the management of adult congenital heart disease: The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD). Eur Heart J. 2021; Vol. 42 (6): 563–645.

297. Frost A., Badesch D., Simon J.R., et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019; 53: 1801904.

298. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016; 37: 67–119.

299. Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Ser. Library of the National Medical Research Center for Cardiology of the Ministry of Health of Russia. M.: OOO Medical Information Agency, 2018. 304 p. (in Russ.)

300. Chazova I.E., Arkhipova O.A., Martynyuk T.V. Pulmonary arterial hypertension in Russia: analysis of a six-year follow-up according to the National Register. Therapeutic archive. 2019; 91(1): 24-32 (in Russ.)

301. Dimopoulos K., Wort S.J., Gatzoulis M.A. Pulmonary hypertension related to congenital heart disease: A call for action. Eur Heart J. 2014; 35: 691–700.

302. Lowe B.S., Therrien J., Ionescu-Ittu R., et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population: impact on outcomes. J Am Coll Cardiol. 2011; 58: 538–46.

303. Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian clinical guidelines, 2020 (in Russ.)

304. Kovacs G., Berghold A., Scheidl S., et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34 (4): 888–94.

305. Kaemmerer H., Apitz C., Brockmeier K., et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J of Cardiology. 2018; 272: 79–88.

306. Gorbachevsky S.V., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Definition, classification and initial examination of patients. Russian Bulletin of Perinatology and Pediatrics. 2021; 66(5):28-37 (in Russ.)

307. Rosenzweig E.B., Abman S.H., Adatia I., et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019; 53(1).

308. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62 (25 Suppl): D34-41.

309. Cantor W.J., Harrison D.A., Moussadji J.S., et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome, Am J. Cardiol. 1999; 84: 677–81.

310. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-537.

311. Stout K.K., Daniels C.J., Aboulhosn J.A., et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e698-e800.

312. Bockeria L.A., Gorbachevsky S.V., Shmalts A.A., et al. Hemodynamic correction of the functionally single ventricle of the heart after previously performed narrowing of the pulmonary artery. Thoracic and cardiovascular surgery. 2008; 5:27-34. (in Russ.)

313. Bockeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart disease in adults (clinical recommendation). Thoracic and cardiovascular surgery. 2017; 59(2): 135-47 (in Russ.)

314. Pulmonary hypertension in children. Russian clinical guidelines, 2017 (in Russ.) http://cr.rosminzdrav.ru/#!/recomend/901.

315. Hypertensive pulmonary vascular disease associated with congenital heart disease in children. Russian clinical guidelines, 2018 (in Russ.) http://cr.rosminzdrav.ru/#!/schema/356.

316. Cerro M.J., Abman S., Diaz G., et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; 1 (2): 286–98.

317. Chazova I.E., Martynyuk T.V. Pulmonary hypertension. Moscow. Practice. 2015, 928 s (in Russ.)

318. Apitz C., Hansmann G., Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2): ii23–9.

319. Moceri P., Kempny A., Liodakis E., et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol. 2015; 179:455–460.

320. Kozlik-Feldmann G., Hansmann, D., et al. Pulmonary hypertension in children with congenital heart disease (PAH-CHD,PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK, Heart 2016; 102 (Suppl 2): i42-ii8.

321. van der Linde D., Konings E.E., Slager M.A., et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241-47.

322. Liu Y., Chen S., Zuhlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019; 48:455-46.

323. Lytzen R., Vejlstrup N., Bjerre J., et al. Live-born major congenital heart disease in Denmark: incidence, detection rate, and termination of pregnancy rate from 1996 to 2013. JAMA Cardiol 2018; 3: 829-37.

324. Moons P., Bovijn L., Budts W., et al. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010; 122: 2264-72.

325. Marelli A.J., Ionescu-Ittu R., Mackie A.S., et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014; 130: 749-56.

326. Van de Bruaene A., Delcroix M., Pasquet A., et al. The Belgian Eisenmenger syndrome registry: Implications for treatment strategies? Acta Cardiol. 2009;64: 447–53.

327. van Riel A.C., Schuuring M.J., van Hessen I.D., et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014; 174: 299-305.

328. Manes A., Palazzini M., Leci E., et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014; 35: 716-24.

329. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004. 126 (1 Suppl):78S–92S.

330. Marelli A.J., Mackie A.S., Ionescu-Ittu R., et al. Congenital heart disease in the general population: Changing prevalence and age distribution. Circulation. 2007; 115: 163–72.

331. Duffels M.G., Engelfriet P.M., Berger R.M. et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007; 120(2 ):198-204.

332. Ramjug S., Hussain N., Hurdman J.. et al. Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic-pathophysiologic classification. J Heart Lung Transplant. 2016. 35(5): 610-18.

333. Diller G.P., Dimopoulos K., Kafka H., et al. Model of chronic adaptation: Right ventricular function in Eisenmenger syndrome. Eur. Heart J. Suppl. 2007; 9: H54–H60.

334. Alonso-Gonzalez R., Lopez-Guarch C.J., Subirana-Domenech M.T., et al. Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. Int J Cardiol. 2015; 184: 717-23.

335. Kempny A., Hjortshøj C.S., Gu H., et al. Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study. Circulation. 2017;135(15):1432-1440.

336. Morse J.H., Barst R.J., Fotino M. Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. Am Rev Respir Dis. 1992; 145:787–92.

337. Roberts K.E., McElroy J.J., Wong W.P., et. al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J. 2004; 24: 371–74.

338. Bockeria L.A., Gorbachevsky S.V., Shmalts A.A. Pulmonary arterial hypertension associated with congenital heart disease in adults. Toolkit. NTSSSH them. A. N. Bakuleva RAMS, 2016 (in Russ.)

339. Khugaev G.A., Shmalts A.A. Morphological assessment of pulmonary vessels in pulmonary hypertension caused by congenital heart defects. Archive of pathology. 2021; 83(5):49–57 (in Russ.)

340. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122 (12): 4306-13.

341. Iacobazzi D., Suleiman M.S., Ghorbel M., et al. Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart. 2016; 102 (1): 12-7.

342. Bradford R., Tulloh R. Diagnosis and management of pulmonary hypertension in adult congenital heart disease. Br J Cardiac Nurs. 2008; 3:138–45.

343. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001. 120(5):1562-69.

344. Gorbachevsky Sv., Shmalts A.A. What can cause pulmonary vascular disease in functionally single ventricle? Anatomy & Physiology: Current Research. 2016; 6 (1). doi 10.4172/2161-0940.1000e137

345. Adatia I., Kothari S.S., Feinstein J.A. Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. Chest 2010; 137 (6 Suppl): 52S-61S.

346. Sharykin A.S. Congenital heart defects. Guidelines for pediatricians, cardiologists, neonatologists.-M.: Teremok.-2005.-381 p (in Russ.)

347. Favoccia C., Constantine A.H., Wort S.J., et al. Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease. Expert Review of Cardiovasc Therapy 2019; 17: 449-59.

348. Baumgartner H., Bonhoeffer P., De Groot N.M., et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European Paediatric Cardiology (AEPC), ESC Committee for Practice Guidelines (CPG). Eur Heart J. 2010; 31(23): 2915-57.

349. Heath D., Edwards J.E. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958; 4 (Part 1): 533-47.

350. Yamaki S., Horiuchi T., Miura M., et al. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest. 1986; 89 (5): 694-8.

351. Heath D., Helmholz H.F. Jr, Burchell H., et al. Relation between structural change in the small pulmonary arteries and the immediate reversibility of pulmonary hypertension following closure of ventricular and atrial septal defects. Circulation. 1958; 18 (6):1167-74.

352. Esipova I.K. Some questions of lung pathology. AN USSR. 1962. (in Russ.)

353. Haworth S.G., Rabinovitch M. Pulmonary circulation. In: Anderson RH, Baker EJ, Penny DJ, Redington AN, Rigby ML, Wernovsky G (eds). Paediatric Cardiology, 3rd edn. Churchill Livingstone, Elsevier, Philadelphia, PA, 2010: 117–141.

354. Rabinovitch M., Haworth S.G., Castaneda A.R., et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978; 58(6): 1107-22.

355. Endo M., Yamaki S., Ohmi M., Tabayashi K. Pulmonary vascular changes induced by congenital obstruction of pulmonary venous return. Ann Thorac Surg. 2000; 69 (1):193-7.

356. Dimopoulos K., Diller G.P., Opotowsky A.R., et al. Definition and Management of Segmental Pulmonary Hypertension. J Am Heart Assoc. 2018;7 (14): e008587.

357. Thiene G., Frescura C., Bini R.M., et al. Histology of pulmonary arterial supply in pulmonary atresia with ventricular septal defect. Circulation. 1979; 60 (5):1066-74.

358. Van Dissel A.C., Mulder B.J., Bouma B.J. The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. J of Clin Med. 2017;. 6 (4): 40.

359. Gorbachevsky S.V., Shmalts A.A., Plotnikova L.R. Pulmonary hypertension in children with congenital heart disease. Moscow. 2018 (in Russ.)

360. Bockeria L.A., Gorbachevsky S.V., Shkolnikova M.A. Pulmonary hypertension in children. Moscow. Actelion Pharmaceuticals; 2013 (in Russ.)

361. Gorbachevsky S.V., Shmalts A.A. Hypertensive pulmonary vascular disease associated with congenital heart disease. In: Bokeria L.A., Shatalov K.V. Children’s cardiac surgery. Guide for doctors. Moscow: NTSSSh im. A.N. Bakulev; 2016: 833– 50. (in Russ.)

362. Hansmann G., Koestenberger M., Alastalo T.P., et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019; 38 (9):879-901.

363. Lammers A.E., Apitz C., Zartner P., et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102 (Suppl 2): ii1–13.

364. Dimopoulos K., Diller G.P. Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017. 368p.

365. Dimopoulos K., Prapa M., Gatzoulis M. Eisenmenger syndrome and other types of pulmonary arterial hypertension related to congenital heart disease. In: Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care. Springer; 2013.

366. Ikegami R., Ozaki K., Ozawa T., et al. Percutaneous Coronary Intervention for a Patient with Left Main Coronary Compression Syndrome. Intern Med. 2018; 57 (10):1421-4.

367. Butera G., Mansour N.B., De Marco F. Emergency transcatheter coronary intervention for left main compression secondary to pulmonary hypertension in a 4-year-old child. Catheter Cardiovasc Interv. 2019; 93(1):105-7.

368. Mamas M.A., Clarke B., Mahadevan V.S. Embolisation of systemic-to-pulmonary collaterals in patients with the Eisenmenger reaction presenting with haemoptysis. Cardiol Young. 2008; 18 (5):528-31.

369. Larici A.R., Franchi P., Occhipinti M., et al. Diagnosis and management of hemoptysis. Diagn Interv Radiol. 2014; 20 (4):299-309.

370. Broberg C.S., Ujita M., Prasad S. et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007; 50 (7): 634–42.

371. Placik B., Rodbard S., McMahon J., Swaroop S. Pulmonary artery dissection and rupture in Eisenmenger’s syndrome. Vasc Surg. 1976; 10 (2):72-80.

372. Areco D., Pizzano N. Pulmonary artery dissection: echocardiographic findings and diagnosis. Echocardiography. 2003; 20 (4): 375-7.

373. Mikhail G.W., Gibbs J.S., Yacoub M.H. Pulmonary and systemic arterial pressure changes during syncope in primary pulmonary hypertension. Circulation. 2001; 104 (11): 1326-7.

374. Moledina S., Hislop A.A., Foster H., et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart. 2010; 96 (17):1401-6.

375. Chazova I. E., Avdeev S. N., Tsareva N. A., et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic archive. 2014; 9:4-23 (in Russ.)

376. Kaemmerrer H., Koichiro N., Oechslin E., et al. Pulmonary Arterial Hypertension in Congenital Heart Disease: Eisenmenger’s Syndrome – A Global Perspectiv. 1st edition. Bremen: UNI-MED; 2013.

377. Oechslin E., Mebus S., Schulze-Neick I., et al. The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects. Cur Cardiol Rev. 2010; 6 (4): 363–72.

378. Labombarda F., Kerros H., Grollier G. Eisenmenger syndrome due to a large ductus arteriosus. Arch Cardiovasc Dis. 2010; 103 (11-12): 623-5.

379. Dimopoulos K. Eisenmenger syndrome in an adult patient with a large patent ductus arteriosus. Eur Respir Rev. 2013; 22(130): 558-64.

380. Ryabykina G.V., Blinova E.V., Sakhnova T.A. Electrovectorcardiographic diagnosis of right ventricular hypertrophy in patients with pulmonary hypertension. Medical alphabet 2017; 8:3-17 (in Russ.)

381. Kamphuis V.P., Haeck M.L., Wagner G.S., et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol. 2014; 47 (2): 175-82.

382. Tongers J., Schwerdtfeger B., Klein G., et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007; 153:127-32.

383. Yurpolskaya L.A., Shmalts A.A. Radiography, X-ray computed and magnetic resonance imaging in pulmonary hypertension associated with congenital heart disease. Children’s diseases of the heart and blood vessels. 2021; 18(2):83-93 (in Russ.)

384. Tsallagova Z.S., Lazutkina V.K. Possibilities of traditional radiography in the assessment of pulmonary arterial hypertension. medical imaging. 2001; 4:59-63. (in Russ.)

385. X-ray diagnostics of diseases of the heart and blood vessels. /Ed. M.A. Ivanitskaya.-M., “Medicine”, 1970. (in Russ.)

386. X-ray diagnostics in pediatrics. Guide for doctors in 2 volumes. /Under the editorship of V.F.Baklanova, A.Filippkin. M.: Medicine, -1988.-T.1.-448 S. (in Russ.)

387. Children’s cardiology. / Ed. J. Hoffman. Translation from English -M .: Practice. -2006.-543С (in Russ.)

388. Korobkova I.Z., Lazutkina V.K., Nizovtsova L.A. Methodological aspects of radiographic assessment of pulmonary hypertension. Bulletin of radiology and radiology. 2015.4:45-53 (in Russ.)

389. Dimopoulos K., Giannakoulas G., Bendayan I., et al. Cardiothoracic ratio from postero-anterior chest radiographs: a simple, reproducible and independent marker of disease severity and outcome in adults with congenital heart disease. Int J Cardiol. 2013.166:453-7.

390. Freedom R.M., Yoo Shi-joon, Mikailian H., Williams W.G. The Natural and Modified History of Congenital Heart Disease. 2008. Wiley-Blackwell-904 p.

391. Freedom R. M., Benson L.N., Smallhorn J.F. Neonatal Heart Disease. Springer-Verlag London 1992, 881p.

392. Koestenberger M., Apitz C., Abdul-Khaliq H., Hansmann G. Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and D6PK. Heart. 2016; 102 (Suppl 2): ii14-22.

393. Anderson R.H., Baker E.J., Penny D.J., et al. Paediatric cardiology. 3d edition. Elsevier, 2009.

394. Baryshnikova I.Yu., Shmalts A.A. Diagnosis of pulmonary hypertension associated with congenital heart disease. Part 2. Echocardiography. Russian Bulletin of Perinatology and Pediatrics. 2021; 66(6): 23–32 (in Russ.)

395. Li W., West C., McGhie J., et al. Consensus recommendations for echocardiography in adults with congenital heart defects from the International Society of Adult Congenital Heart Disease (ISACHD). Int J Cardiol. 2018; 272:77-83.

396. Augustine D.X., Coates-Bradshaw L.D., Willis J., et al. BSE pulmonary hypertension guideline 2018; 5 (3): G11–G24.

397. Rudski LG., Lai W.W., Afi lalo J., et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23: 685-713.

398. Zaidi A., Knight D.S., Augustine D.X., et al. Echocardiographic assessment of the right heart in adults: a practical guideline from the British Society of Echocardiography. 2020; 7 (1): G19–G41.

399. Amsallem M., Sternbach J.M., Adigopula S., et al. Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr. 2016; 29: 93–102.

400. Fisher M.R., Forfia P.R., Chamera E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 (7): 615-21.

401. Rimington H., Chambers J.B. Echocardiography: a practical guide for reporting and interpretation. Third edition. CRC Press; 2016.

402. Lang R.M., Badano L.P., Mor-Avi V., et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Society of Echocardiography. 2015; 28 (1): 1–39.

403. Abraham S., Weismann C.G. Left ventricular end-systolic eccentricity index for assessment of pulmonary hypertension in infants. Echocardiography. 2016; 33: 910–15.

404. Nagueh S.F., Smiseth O.A., Appleton C.P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29:277-314.

405. Friedberg M., Merten L. Tissue velocities, strain, and strain rate for echocardiographic assessment of ventricular function in congenital heart disease. European J Echocardiography. 2009; 10: 585-93.

406. Lai W.W., Mertens L.L., Cohen M.S., Geva T. Echocardiography in pediatric and congenital heart disease. From Fetus to Adult. Second Edition. Wiley Blackwell; 2016.

407. Moceri P., Li W., Dimopoulos K. Echocardiography in the Diagnosis and Follow-Up of Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

408. Bockeria LA, Baryshnikova I.Yu., Gorbachevsky S.V. Echocardiography in the diagnosis and evaluation of pulmonary hypertension. Tutorial. Moscow. 2017 (in Russ.)

409. Mertens L., Friedberg M.K. Systolic ventricular function. In: Echocardiography in Pediatric and Congenital Heart Disease: From Fetus to Adult; 2016, Hoboken, US: Wiley-Blackwell, p.96-131.

410. Gurudevan S.V., Malouf P.J., Kahn A.M., et al. Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. J Am Soc Echocardiogr. 2007; 20 (10):1167–71.

411. Sutherland G.R., Di Salvo G., Claus P., et al. Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function. J Am Soc Echocardiogr 2004; 17: 788-802.

412. D’Alto M., Dimopoulos K., Budts W., et al. Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension. Heart. 2016; 102 (12): 910-18.

413. Puchalski M.D., Lui G.K., Miller-Hance W., et al. Guidelines for Performing a Comprehensive Transesophageal Echocardiographic. Journal of the American Society of Echocardiography. 2019; 32 (2): 173–215.

414. Sharia A.M., Martynyuk T.V., Ternovoy S.K., Sharia M.A. Possibilities of magnetic resonance imaging in the diagnosis of pulmonary arterial hypertension. Cardiology. 2021;61(6):97-104. (in Russ.)

415. Bockeria L.A., Makarenko V.N., Yurpolskaya L.A. Computed and magnetic resonance imaging in the diagnostic algorithm for congenital heart defects: What? When? To whom? -“for” and “against”. Thoracic and cardiovascular surgery 2014; 3:4-13 (in Russ.)

416. Latus H., Kuehne T., Beerbaum Ph., et all. Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/ pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016; 102: ii30–ii35.

417. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007. 28:1250-7.

418. Belokon N.A., Podzolkov V.P., Mitrofanov I.O. Congenital heart disease .-M .: Medicine .-1990.-352p. (in Russian).

419. Brignole M., Auricchio A., Baron-Esquivias G., et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013; 34: 2281-329.

420. Radenkovic D., Weingärtner S., Ricketts L., et al. T1 mapping in cardiac MRI. Heart Fail Rev. 2017; 22:415–430,

421. Salerno M., Sharif B., Arheden H., et al. Recent Advances in Cardiovascular Magnetic Resonance Techniques and Applications. Cir.cCardiovasc.Imaging. 2017; 10 :e003951.

422. European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restric

423. Odagiri K., Inui N., Hakamata A., et al. Noninvasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. Springer Plus 2016; 5: 1071

424. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 2007; 28: 1187-1189.

425. Perloff J.K., Marelli A. Perloff’s Clinical Recognition of Congenital Heart Disease: Expert Consult Online and Print, 6e. 6th edition. Philadelphia: Saunders; 2012

426. de Siqueira M.E.M.., Pozo E., Fernandes V.R., et all. Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. J of Cardiovasc Magn Res-2016; doi 10.1186/s12968-016-0258-x

427. Tello K., Dalmer A., Vanderpool R., et al. Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC Cardiovasc Imaging. 2019;12 (1): 2155-64.

428. X-ray diagnostics of diseases of the heart and blood vessels. Ed. M.A. Ivanitskaya. M., “Medicine”, 1970. (in Russ.)

429. Makarenko V.N., Yurpolskaya L.A., Zelenikin M.M., Shinkareva T.V. Computed tomography in the evaluation of patients after Fontan surgery. Bulletin of the NCSSH them. A.N. Bakulev RAMS. 2010; 11(1):46-50 (in Russ.)

430. Kilner P., Nichol E., Rubens M. The roles of CT and CMR in Adult Congenital Heart Disease. In: ESC Textbook of Cardiovascular Imaging. 2nd ed, Oxford:Oxford University Press; 2015, p. 563-600.

431. Grosse-Wortmann L., Drolet Chr., Dragulescu An., et al. Aortopulmonary collateral flow volume affects early postoperative outcome after Fontan completion: A multimodality study. J. Thorac. Cardiovasc. Surg. 2012; 144: 1329-36.

432. Habib G., Lancellotti P., Antunes M.J., et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36: 3075-3128.

433. Ohno Y., Koyama H., Lee H.Y., Miura S.t all. Contrast-enhanced CT-and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagn Interv Radiol-2016; 22: 407–421

434. Pienn M., Kovacs G., Tscherner M., Avian A. et all. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study. Eur Radiol.-2014; 24:668–676

435. Sobolev A.V., Shmalts A.A. Endovascular diagnosis of pulmonary hypertension associated with congenital heart disease. Part 1. Cardiac catheterization and angiocardiography. Endovascular surgery. 2021; 8(3):263–71 (in Russ.)

436. Guillinta P., Peterson K.L., Ben-Yehuda O. Cardiac catheterization techniques in pulmonary hypertension. Cardiol Clin. 2004; 22: 401–15.

437. Peterson K.L., Nicod P. Cardiac catheterization: methods, diagnosis, and therapy. Saunders, Philadelphia; 1997

438. Barnett C., Ben-Yehuda О. Cardiac Catheterization in the Patient with Pulmonary Hypertension. Textbook of Pulmonary Vascular Disease Springer, Science+Business Media, LLC; 2011

439. Gorbachevsky S.V., Belkina M.V., Koledinsky D.G., et al. Invasive pulmonary artery pressure monitoring is an objective method for assessing the severity of pulmonary hypertension in children with congenital heart disease. Children’s diseases of the heart and blood vessels. 2006; 4:77–81 (in Russ.)

440. Wilkinson J.L. The Fontan сirculation. Results, late Follow-up and management. Heart Views. 2004; 4 (4): 73-78.

441. Fredenburg T.B., Johnson T.R., Cohen M.D. The Fontan Procedure: Anatomy, Complications, and Manifestations of Failure. RadioGraphics. 2011;31(2): 453–463.

442. Bergersen L., Foerster S., Marshall A.C., Meadows J. (eds). Congenital heart disease: the catheterization manual. Springer, New York; 2009.

443. Bockeria L.A., Alekyan B.G. (ed.). Guide to X-ray endovascular surgery of the heart and vessels. Moscow, NTSSSh im. A.N. Bakulev RAMS; 2008 (in Russ.)

444. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111: 3105–11.

445. Barst R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986; 89: 497–503.

446. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76–81.

447. Douwes J.M., van Loon RLE, Hoendermis E.S, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011; 32 (24): 3137-46.

448. Chessa M. Cardiac Catheterization. In: Dimopoulos K, Diller G.P. (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

449. Hoeper M.M., Lee S.H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006; 48: 2546–52.

450. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: Comparative severity, correlates, and prognostic implication. Circulation. 2005. 112:828–35.

451. Savarese G., Paolillo S., Costanzo P., et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: a meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192–1201.

452. Gabler N.B., French B., Strom B.L, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126: 349–56.

453. Glushko L.A., Shmalts A.A. Assessment of the state of the cardiorespiratory system in pulmonary hypertension associated with congenital heart disease. Creative cardiology. 2021; 15(2): 167-179. (in Russ.)

454. Arena R., Lavie C.J., Milani R.V., et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010; 29 (2): 159-73.

455. Johnson M.K., Thompson S. The role of exercise testing in the modern management of pulmonary arterial hypertension. Diseases. 2014; 2: 120-47.

456. Wasserman K., Hansen J.E., Sue D.Y., et al. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. Fifth edition. Philadelphia: Lippincott Williams & Wilkins; 2012, 572 p.

457. Seeger W., Adir Y., Barbera J.A., et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62: D109–16.

458. Johnson J.T., Yetman A.T. Cardiopulmonary exercise testing in adults with congenital heart disease. Prog Pediatr Cardiol. 2012; 34: 47–52.

459. Laveneziana P., Garcia G., Joureau B. et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J. 2013. 41:578-587.

460. Ferrazza A.M., Martolini D., Valli G., Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009; 77 (1): 3-17.

461. Mantegazza V., Apostolo A, Hager A. Cardiopulmonary Exercise Testing in Adult Congenital Heart Disease. Ann Am Thorac Soc. 2017; 14 (Suppl.1): S93-S101.

462. Diller G.P., Kempny A., Inuzuka R., et al. Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart. 2014; 100(17): 1366-72.

463. Buys R., Cornelissen V., Van De Bruaene A., et al. Measures of exercise capacity in adults with congenital heart disease. Int J Cardiol. 2011; 153 (1): 26-30.

464. Taran I.N., Valieva Z.S., Martynyuk T.V., et al. Spiroveloergometry in risk stratification of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eurasian Cardiology Journal. 2017; 4:86-92. {in Russ.)

465. Zhao Q.H., Wang L., Pudasaini B., et al. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension. Clin Cardiol. 2017; 40 (2): 95-101.

466. Chazova I.E., Martynyuk T.V. et al. Diagnosis and treatment of pulmonary hypertension. Russian recommendations. Cardiovascular Therapy and Prevention 2007; 6: Appendix 2. (in Russ.)

467. Sun X.G., Hansen J.E., Oudiz R.J, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41:1028–35.

468. Alonso-Gonzalez R., Borgia F., Diller G.P., et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. 2013; 127 (8): 882-90.

469. Ferguson G.T., Enright P.L., Buist A.S., Higgins M.W. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest. 2000;117 (4): 1146-61.

470. Arkhipova O.A., Martynyuk T.V., Samoilenko L.E., et al. Perfusion lung scintigraphy in patients with pulmonary hypertension of various etiologies. Eurasian Cardiology Journal. 2015; 4:21-25 (in Russ.) https://doi.org/10.38109/2225-1685-2015-4-21-25

471. Tunariu N., Gibbs S.R., Win Z., et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007; 48: 680-84.

472. Albrecht T., Blomley M.J., Cosgrove D.O., et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet. 1999; 353: 1579-83.

473. Perloff J.K. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993; 11: 689-99.

474. Giannakoulas G., Mouratoglou S., Gatzoulis M.A.. et al. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. International Journal of Cardiology. 2014; 174 (3): 618–23.

475. Fenster B.E., Lasalvia L, Schroeder J.D., et al. Cystatin C for pulmonary hypertension. Respirology. 2014. 19: 583-89.

476. Scognamiglio G., Kempny A., Price L.C., et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart. 2014. 100:1335-1341.

477. Dimopoulos K., Okonko D.O., Diller G.P., et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006; 113 (24): 2796-802.

478. Deanfield J., Thaulow E., Warnes C., et al. Management of grown-up congenital heart disease. Eur Heart J. 2003; 24: 1035-84.

479. Yang-Ting S., Aboulhosn J., Sun X.G. et al. Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome. Congenit Heart Dis. 2011; 6 (2): 139-46.

480. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121: 20-25.

481. Diller G.P., Korten M.A., Bauer U.M., et al. German Competence Network for Congenital Heart Defects Investigators. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J 2016; 37: 14491455.

482. Oster M., Bhatt A., Zaragoza-Macias E., et al. Interventional therapy versus medical therapy for secundum atrial septal defect: a systematic review (part 2) for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e000–000.

483. Shah D., Azhar M., Oakley C.M., et al. Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J. 1994; 71: 224–27.

484. Cho Y.H., Jun T-G., Yang J-H., et al. Surgical strategy in patients with atrial septal defect and severe pulmonary hypertension. Heart Surg Forum. 2012; 15:E111–5. S4.1.1-21.

485. Kouchoukos N.T., Blackstone E.H., Kirklin J.W. Surgical implications of pulmonary hypertension in congenital heart disease. Adv Cardiol. 1978: S4: 225–31

486. Yan C., Zhao S., Jiang S., et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007; 93: 514–18.

487. Gamboa R., Rios-Méndez R.E., Mollón F.P., et al. Percutaneous closure of patent ductus arteriosus in adults using different devices. Rev Esp Cardiol. 2010; 63: 726–29.

488. Jeong Y-H., Yun T-J., Song J-M., et al. Left ventricular remodeling and change of systolic function after closure of patent ductus arteriosus in adults: device and surgical closure. Am Heart J. 2007; 154: 436–40.

489. Zabal C., García-Montes J.A., Buendía-Hernández A., et al. Percutaneous closure of hypertensive ductus arteriosus. Heart. 2010; 96: 625–29.

490. Lim D.S., Forbes T.J., Rothman A., et al. Transcatheter closure of high-risk muscular ventricular septal defects with the CardioSEAL occluder: initial report from the CardioSEAL VSD registry. Catheter Cardiovasc Interv. 2007; 70 (5): 740-44.

491. Chessa M., Butera G., Negura D., et al. Transcatheter closure of congenital ventricular septal defects in adult: mid-term results and complications. Int J Cardiol. 2009; 133 (1):70-3.

492. Gorbachevsky S.V., Shmalts A.A. Palliative atrial and arterial switching in transposition of the main arteries with ventricular septal defect and severe pulmonary vascular disease. Children’s diseases of the heart and blood vessels. 2019; 16(2): 86-94 (in Russ.)

493. Petrosyan K.V., Gorbachevsky S.V., Dadabaev G.M., Pardaev D.B. Stenting of the trunk of the left coronary artery in a patient with pulmonary hypertension. Eurasian Cardiology Journal. 2017; 3:86-87 (in Russ.)

494. Gorbachevsky S.V., Shmalts A.A., Dadabaev G.M., et al. Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort. Diagnostics (Basel). 2020; 10(9): 725.

495. Gorbachevsky S.V., Pursanov M.G., Shmalts A.A., et al. Results of atrioseptostomy with stenting in patients with idiopathic and similar forms of pulmonary arterial hypertension. Thoracic and cardiovascular surgery. 2019; 61(2): 100-113. (in Russ.)

496. Shmalts A.A., Nishonov N.A. Atrioseptostomy in patients with pulmonary hypertension. Thoracic and cardiovascular surgery. 2015; 57(5): 18-25 (in Russ.)

497. Christie J.D., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult lung and heart-lung transplant report 2012. J. Heart Lung Transplant. 2012; 31:1073–86.

498. Fadel E., Mercier O., Mussot S., et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg. 2010; 38: 277–84.

499. Hopkins W.E., Ochoa L.L., Richardson G.W., et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996; 15 (1):100-5.

500. Moons P., De Geest S., Budts W. Comprehensive care for adults with congenital heart disease: expanding roles for nurses. Eur J Cardiovasc Nurs. 2002; 1: 23-28.

501. Baumgartner H., Budts W., Chessa M., et al, Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. Recommendations for organization of care for adults with congenital heart disease and for training in the subspecialty of ‘Grown-up Congenital Heart Disease’ in Europe: a position paper of the Working Group on Grown-up Congenital Heart Disease of the European Society of Cardiology. Eur Heart J. 2014; 35: 686-90.

502. Thomet C., Moons P., Budts W., et al. ESC Working Group on Grown-up Congenital Heart Disease. Staffing, activities, and infrastructure in 96 specialised adult congenital heart disease clinics in Europe. Int J Cardiol 2019; 292: 100-105.

503. Popelová J., Oechslin E., Kaemmerer H., Sutton M. Congenital Heart Disease in Adults 2008 Informa UK Ltd.-183p.

504. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J., et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39: 31653241.

505. Sliwa K., van Hagen I.M., Budts W., et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016; 18 (9): 1119–28.

506. Jaı ̈s X., Olsson K.M, Barbera J.A., et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012; 40: 881–85.

507. Kovacs A.H., Sears S.F., Saidi A.S. Biopsychosocial experiences of adults with congenital heart disease: review of the literature. Am Heart J 2005; 150: 193-201.

508. Raines D.E., Liberthson R.R., Murray J.R. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger’s physiology. J Clin Anesth. 1996; 8: 341–47.

509. Grünig, E., Benjamin, N., Krüger, U., et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018.

510. Blanche C., Alonso-Gonzalez R., Uribarri A. et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol. 2018. 267:79-83.

511. Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 577.

512. Olsson K.M., Delcroix M., Ghofrani H.A., et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014; 129: 57–65.

513. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.

514. Steffel J., Verhamme P,. Potpara T.S., et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39:1330-93.

515. Pujol C., Niesert A.C., Engelhardt A., et al. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol. 2016; 117: 450-55.

516. Yang H., Bouma B.J., Dimopoulos K., et al. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol. 2019; 299: 123-30.

517. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001; 164:1682–87.

518. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985; 131: 493-98.

519. van de Veerdonk M.C., Kind T., Marcus J.T., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011; 58: 2511-19.

520. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998; 114: 787-92.

521. Arkhipova O.A., Martynyuk T.V., Chazova I.E. Features of tactics of management and choice of specific therapy in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Eurasian Cardiology Journal. 2018.1:48-53 (in Russ.)

522. Shmalts A.A., Gorbachevsky S.V. Evidence base for specific pulmonary vasodilators in children with congenital heart disease. Pediatrics. Journal them. G.N. Speransky. 2017: 96(6):126-139 (in Russ.)

523. Shmalts A.A., Gorbachevsky S.V. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Therapeutic archive. 2021; 93(9): 1106-1116 (in Russ.)

524. Shmalts A.A., Belkina M.V., Gorbachevsky S.V. Specific pulmonary vasodilators after Fontan operation. Children’s diseases of the heart and blood vessels. 2017; 14(1): 16-24 (in Russ.)

525. Traclear®. Instructions for use of a medicinal product for medical use. LS-002509. (in Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=93619b5d-c8c6-4bdb-b201-88aff22c785c&t=

526. Bosenex. Instructions for medical use of the use of the medicinal product. LP-004208. (in Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=68d79ec9-1045-403c-be20-e88cc33f0aa6&t=

527. Opsumite®. Instructions for use of a medicinal product for medical use. LP-003310. (in Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b2c51f9d-696d-4b23-881a-8c8d0fec4b96&t=

528. Upbravi. Instructions for use of a medicinal product for medical use.LP-005577. (in Russ.) https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=094dda8d-ba79-4353-83f9-98ea68b865aa&t=

529. Manes A. PAH in Patients with Prevalent Systemic–Pulmonary Shunts and PAH in Patients with Small Cardiac Defects. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017

530. Idorn L., Sondergaard L. Pulmonary Vascular Disease in Patients with Fontan-Type Circulation. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

531. Moledina Sh., Theocharis P. Pulmonary Arterial Hypertension in Patients with Previous Reparative Surgery. In: Dimopoulos K, Diller GP (eds). Pulmonary Hypertension in Adult Congenital Heart Disease. Springer; 2017.

532. Shmalts A.A., Gorbachevsky S.V. Opportunities and limitations for initial combined specific therapy of pulmonary arterial hypertension in the Russian Federation. Therapeutic archive. 2020; 92(12): 80-85. (in Russ.)

533. D’Alto M., Diller G.P. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014; 100 (17):1322-28.

534. Chazova I.E., Martynyuk T.V., Nakonechnikov S.N. Endothelin receptor antagonists in pulmonary arterial hypertension: yesterday, today and tomorrow. Russian Journal of Cardiology 2009; 4:73–81 (in Russ.)

535. Galie N., Manes A., Palazzini M., et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008. 68:1049–66.

536. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896–903.

537. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114 (1): 48–54.

538. Gatzoulis M.A., Beghetti M., Galie N., et al. Long-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008; 127 (1): 27-32.

539. Galiè N., Rubi.n L., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371 (9630): 2093-100.

540. Sitbon O., Beghetti M., Petit J., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest. 2006; 36 Suppl 3: 25-31.

541. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest. 2006; 129 (4):1009-15.

542. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007; 93 (8): 974-76.

543. Durongpisitkul K., Jakrapanichakul D., Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. J Med Assoc Thai. 2008; 91 (2): 196-202.

544. Duffels M.G., Vis J.C., van Loon R.L, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009; 103 (9): 1309-15.

545. Vis J.C., Duffels M.G., Mulder P., et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013; 164 (1): 64-9.

546. Baptista R, Castro .G, da Silva A.M., et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013; 32 (2): 123-29.

547. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.

548. Gatzoulis M.A., Landzberg M., Beghetti M., et al. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019; 139 (1): 51-63.

549. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 :2148–57.

550. Lu X.L., Xiong C.M., Shan G.L., et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010; 28 (6): 350-55.

551. Chau E.M., Fan K.Y., Chow W.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120 (3): 301-5.

552. Zeng W.J., Lu X.L, Xiong C.M., et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol. 2011; 34 (8): 513-18.

553. Iversen K., Jensen A.S., Jensen T.V., et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 31 (9):1124-31.

554. Ghofrani H. A., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4): 330-40.

555. Shmalts A.A., Gorbachevsky S.V. Riociguat and sildenafil in the treatment of pulmonary hypertension: similarities and differences. Pulmonology 2016; 26(1): 85-91. (in Russ.)

556. Valieva Z.S., Gratsianskaya S.E., Martynyuk T.V. The use of riociguat for the treatment of patients with chronic thromboembolic pulmonary hypertension. Cardiology. 2020; 60(8):115-23. (in Russ.)

557. Stasch J.P., Pacher P., Evgenov O.V. Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation 2011; 123: 2263-2274.

558. Rubin L.J., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015; 45 (5): 1303-13.

559. Rosenkranz S., Ghofrani H.A., Beghetti M., et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101 (22): 1792-99.

560. Cha K.S., Cho K.I., Seo J.S., et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013; 112 (11):1834-39.

561. Chon M.K., Cho K.I., Cha K.S., et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome. J Cardiol. 2017; 69 (5):741-46.

562. Sitbon O., Channick R., Chin K.M., et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373 (26): 2522-33.

563. Beghetti M., Channick R.N., Chin K.M., et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019; 21 (3): 352-59.

564. Hascoet S, Fournier E, Jaïs X., et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Arch Cardiovasc Dis. 2017;110(5):303-316

565. Li Q., Kuang H.Y., Wu Y.H., et al. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98 (20): e15632.

566. D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155(3):378-82

567. Varela D.L., Teleb M., El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart. 2018; 5 (1): e000744.

568. Brida M., Gatzoulis M.A. Pulmonary arterial hypertension in adult congenital heart disease. Heart. 2018; 104 (19): 1568-74.

569. D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155(3):378-82

570. Schuuring M.J., Bouma B.J., Cordina R., et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol. 2013; 164 (1): 106-10.

571. Hebert A, Mikkelsen UR, Thilen U, et al., Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014; 130(23):2021-30.

572. Agnoletti G., Gala S., Ferroni F., et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg. 2017; 153 (6): 1468-75.

573. Schuuring M.J., Vis J.C., van Dijk A.P., et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013; 15 (6): 690-98.

574. Giardini A., Balducci A., Specchia S., et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008; 29 (13): 1681-87.

575. Van De Bruaene A., La Gerche A., et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging. 2014; 7 (2): 265-73.

576. Blok I.M., van Riel A.C.M.J., van Dijk A.P.J., et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol. 2017; 227: 51-52.

577. Gelatt M., Hamilton R.M., et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997; 29: 194-201.

578. Dearani J.A., Danielson G.K., Puga F.J., et al. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg. 2003;75:399-410.

579. Redington AN, Somerville J. Stenting of aortopulmonary collaterals in complex pulmonary atresia. Circulation 1996;94:2479-84.

580. Giannakoulas G., Gatzoulis M.A. Pulmonary arterial hypertension in congenital heart disease: current perspectives and future challenges. Hellenic J Cardiol 2016; 57:218-22.

581. Van De Bruaene A., Toh N., et al. Pulmonary hypertension in patients with a subaortic right ventricle: prevalence, impact and management. Heart 2019;105:1471-78.

582. De Pasquale G., Bonassin Tempesta F, Lopes BS, et al. High prevalence of baffle leaks in adults after atrial switch operations for transposition of the great arteries. Eur Heart J Cardiovasc Imaging. 2017; 18: 531-35.

583. Rydman R., Gatzoulis M.A., Ho S.Y., et al. Systemic right ventricular fibrosis detected by cardiovascular magnetic resonance is associated with clinical outcome, mainly new-onset atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great arteries. Circ Cardiovasc Imaging. 2015; 8: e002628.

584. Zaragoza-Macias E., Zaidi A.N., Dendukuri N., Marelli A. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73: 1564-78.

585. Voet A., Rega F., de Bruaene A.V., et al. Long-term outcome after treatment of isolated pulmonary valve stenosis. Int J Cardiol. 2012; 156: 11-15.

586. Raissadati A., Nieminen H., Sairanen H., Jokinen E. Outcomes after the Mustard, Senning and arterial switch operation for treatment of transposition of the great arteries in Finland: a nationwide 4-decade perspective. Eur J Cardiothorac Surg. 2017; 52: 573-80.

587. Hernandez-Madrid A., Paul T., Abrams D., et al. ESC Scientific Document Group. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital Heart Disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace. 2018; 20:1719-53.

588. Redington A.N., Somerville J. Stenting of aortopulmonary collaterals in complex pulmonary atresia. Circulation. 1996; 94: 2479-84.

589. Hsu C.H., Gomberg-Maitland M., Glassner C. et al. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl. 2011; 172: 6-14.

590. Neutze J.M., Ishikawa T., Clarkson P.M., et al. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol 1989; 63: 327-31.

591. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome. Factors relating to deterioration and death, Eur. Heart J. 1998; 19: 1845–55.

592. Oya H., Nagaya N., Satoh T., et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart. 2000; 84: 53–58.